Phospho-NTRK1 (Y757) Antibody

What is NTRK1 and why is phosphorylation at Y757 significant?

NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1) encodes the TrkA receptor, a high-affinity receptor for Nerve Growth Factor (NGF). TrkA is critically involved in the development and maturation of both central and peripheral nervous systems through regulation of neuronal proliferation, differentiation, and survival . Upon NGF binding, TrkA undergoes homodimerization and autophosphorylation at multiple tyrosine residues, including Y496, Y676, Y680, Y681, and Y791 . While Y757 is not among the most studied phosphorylation sites in the literature, phosphorylation at tyrosine residues in TrkA generally serves as docking sites for adaptor proteins containing SH2 or PTB domains, including SHC1, PLCγ, and GAB1 . These interactions initiate downstream signaling cascades that regulate neuronal survival and differentiation.

Methodologically, when studying NTRK1 phosphorylation, researchers should employ site-specific phospho-antibodies in combination with total NTRK1 antibodies to accurately determine the activation status of the receptor in various experimental contexts.

What techniques can be effectively implemented with Phospho-NTRK1 (Y757) antibodies?

Phospho-NTRK1 (Y757) antibodies are versatile tools applicable across multiple experimental techniques:

For optimal results in IHC applications, researchers should employ appropriate antigen retrieval methods that preserve phospho-epitopes, typically using citrate or EDTA-based buffers at controlled pH . When performing quantitative analyses, validation experiments should include phosphatase-treated negative controls to confirm antibody specificity for the phosphorylated form of the protein.

How can researchers differentiate between NTRK1, NTRK2, and NTRK3 signaling experimentally?

While all three neurotrophin receptors (TRKA, TRKB, and TRKC encoded by NTRK1, NTRK2, and NTRK3 respectively) share structural similarities, they respond to different neurotrophins and activate partially overlapping but distinct signaling pathways .

To experimentally differentiate between these receptors:

• Employ selective ligands: NGF preferentially activates TRKA, BDNF and NT-4 activate TRKB, and NT-3 primarily activates TRKC (though it can also activate TRKA to promote axonal extension without affecting neuron survival) .

• Use receptor-specific antibodies: When selecting antibodies, verify they don't cross-react with other TRK family members by consulting validation data and conducting control experiments with cells expressing only one receptor type.

• Monitor downstream pathway activation: Each receptor has some preference for specific adaptor proteins and downstream pathways. For example, while all three can activate MAPK and PI3K/AKT pathways, they do so with different kinetics and magnitude depending on cell type and context .

Understanding these distinctions is particularly important when investigating neurological disorders or cancers where multiple neurotrophin receptors may be expressed simultaneously.

How does phosphorylation at Y757 compare functionally to other NTRK1 phosphorylation sites?

The functional significance of different phosphorylation sites on NTRK1 varies based on their location and role in recruiting specific adaptor proteins. From the literature:

• Y496 (in the juxtamembrane domain) and Y791 (in the C-terminal tail) are well-characterized sites that directly bind and activate signaling molecules. Y496 binds SHC and FRS2, whereas Y791 interacts with PLCγ .

• Y676, Y680, and Y681 are located within the activation loop of the kinase domain, and their phosphorylation is required for full activation of the kinase .

When designing experiments to study Y757 phosphorylation specifically, researchers should:

• Use phospho-specific antibodies in combination with phospho-mimetic (Y→E) and phospho-deficient (Y→F) mutants to dissect the specific contribution of Y757.

• Perform comparative analyses of downstream signaling activation (MAPK, PI3K/AKT, PLCγ) when Y757 is mutated versus other key phosphorylation sites.

• Consider temporal dynamics of phosphorylation, as different sites may be phosphorylated with different kinetics following ligand stimulation.

What considerations are important when using Phospho-NTRK1 (Y757) antibodies in cancer research?

NTRK1 gene fusions have emerged as important oncogenic drivers across multiple cancer types, with varying frequencies:

When using Phospho-NTRK1 (Y757) antibodies in cancer research, particularly in the context of NTRK fusions, researchers should consider:

• Fusion architecture: Determine whether the Y757 residue is preserved in the fusion protein. Some fusions may disrupt or alter the kinase domain structure, potentially affecting phosphorylation patterns. This is analogous to the situation with Y516 of TRKC, which is absent from the ETV6-NTRK3 fusion protein due to the genomic breakpoint location .

• Activation mechanisms: NTRK fusion proteins often exhibit ligand-independent activation. Therefore, phosphorylation at Y757 may occur constitutively rather than in response to NGF stimulation as in wild-type NTRK1 .

• Downstream signaling differences: Fusion proteins may preferentially activate certain downstream pathways. For example, ETV6-NTRK3 fusion has been shown to engage signaling through IRS-1 and simultaneously activate both RAS-MAPK and PI3K/AKT pathways .

• Resistance mechanisms: When studying TRK inhibitor resistance, phosphorylation patterns including at Y757 may provide insights into altered signaling in resistant tumors.

How can researchers validate the specificity of Phospho-NTRK1 (Y757) antibodies?

Validating phospho-specific antibodies is crucial for generating reliable research data. For Phospho-NTRK1 (Y757) antibodies, implement the following validation strategies:

• Phosphatase treatment controls: Treat one sample set with lambda phosphatase before immunoblotting or immunostaining. Loss of signal confirms phospho-specificity.

• Stimulation/inhibition experiments:

  • Positive control: Stimulate cells with NGF (50-100 ng/ml for 5-15 minutes) to induce NTRK1 phosphorylation

  • Negative control: Pre-treat cells with TRK inhibitors (e.g., larotrectinib or entrectinib) before NGF stimulation

• Genetic validation: Use NTRK1 knockout cell lines or NTRK1-Y757F mutant-expressing cells as negative controls.

• Peptide competition: Pre-incubate the antibody with the immunizing phosphopeptide, which should abolish specific signals.

• Cross-reactivity assessment: Test the antibody against other phosphorylated TRK family members (TRKB/NTRK2 and TRKC/NTRK3) to ensure it doesn't recognize similar phosphorylation sites in these related proteins.

Document all validation experiments thoroughly, including negative and positive controls, to establish confidence in the specificity of observed signals.

What experimental controls are essential when studying NTRK1 Y757 phosphorylation?

Robust experimental design for studying NTRK1 Y757 phosphorylation requires the following controls:

• Stimulation controls:

  • Unstimulated (basal) condition

  • NGF-stimulated (optimal dose: 50-100 ng/ml; time course: 5, 15, 30, 60 minutes)

  • Other neurotrophin-stimulated (NT-3 can activate TRKA for axonal extension)

• Inhibition controls:

  • TRK family inhibitor treatment (larotrectinib or entrectinib)

  • Selective inhibitors of downstream pathways (MEK inhibitors, PI3K inhibitors, PLCγ inhibitors)

• Specificity controls:

  • Phosphatase-treated samples

  • Y757F mutant NTRK1 expression (phospho-deficient)

  • Y757E mutant NTRK1 expression (phospho-mimetic)

• Cellular context controls:

  • Cell lines with varying levels of p75NTR expression (since p75NTR modulates TRKA responsiveness to neurotrophins)

  • Comparison across neuronal and non-neuronal cell types

When designing time-course experiments, consider that receptor internalization following activation may affect phosphorylation dynamics. Additionally, include total NTRK1 detection in parallel to normalize phosphorylation levels and account for potential changes in receptor expression.

How should researchers optimize immunohistochemistry protocols for Phospho-NTRK1 (Y757) detection in tissue specimens?

Detecting phospho-epitopes in tissue specimens presents unique challenges due to rapid phosphatase activity during tissue processing. Optimize IHC protocols with these methodological considerations:

• Tissue fixation:

  • Immediate fixation is critical (within 15-30 minutes of specimen collection)

  • Use phosphatase inhibitor cocktails in fixatives (e.g., 1 mM sodium orthovanadate, 10 mM sodium fluoride)

  • Formalin fixation time should be standardized (18-24 hours recommended)

• Antigen retrieval:

  • Test multiple buffers: citrate (pH 6.0), EDTA (pH 8.0-9.0), and Tris-EDTA with 0.05% Tween

  • Optimize retrieval duration (typically 15-20 minutes)

  • Include phosphatase inhibitors in retrieval solutions

• Blocking and antibody incubation:

  • Extended blocking (1-2 hours) with 5-10% normal serum plus 1% BSA

  • Optimal antibody dilution range: 1:100-1:300 for IHC applications

  • Consider overnight incubation at 4°C to improve sensitivity

• Signal amplification and detection:

  • Tyramide signal amplification systems for low-abundance phospho-proteins

  • Polymer-based detection systems reduce background

• Validation with control tissues:

  • Include tissues known to express activated NTRK1 (e.g., specific neuronal populations, certain tumor types)

  • Adjacent sections treated with lambda phosphatase as negative controls

For quantitative analysis, use digital image analysis software with appropriate thresholding to distinguish specific staining from background and report results as H-scores or percent positive cells with intensity gradations.

What approaches are recommended for studying NTRK1 Y757 phosphorylation dynamics in response to different ligands?

To comprehensively analyze NTRK1 Y757 phosphorylation dynamics in response to different ligands, implement these methodological approaches:

• Dose-response experiments:

  • NGF concentration series (0.1, 1, 10, 50, 100 ng/ml)

  • NT-3 concentration series (may activate TRKA for axonal extension)

  • Pro-NGF (binds p75NTR and can modulate TRKA signaling)

• Time-course analysis:

  • Short-term: 1, 5, 15, 30, 60 minutes (captures immediate receptor activation)

  • Long-term: 3, 6, 12, 24 hours (reveals adaptation and feedback regulation)

• Multiplexed signaling analysis:

  • Simultaneous detection of multiple phosphorylation sites (Y496, Y676/680/681, Y757, Y791)

  • Correlation with downstream pathway activation (phospho-ERK, phospho-AKT, phospho-PLCγ)

• Single-cell analysis techniques:

  • Phospho-flow cytometry for cellular heterogeneity assessment

  • Immunofluorescence with high-content imaging to analyze subcellular localization

• Live-cell imaging approaches:

  • FRET-based biosensors for real-time NTRK1 conformational changes

  • Fluorescently-tagged SH2 domains that bind specifically to phosphorylated tyrosines

When comparing ligand responses, consider the influence of p75NTR co-expression, which modulates TRKA responsiveness to neurotrophins. The presence of p75NTR increases the rate of NGF association with TRKA and is required for high-affinity interactions between NGF and TRKA .

What factors might cause loss of Phospho-NTRK1 (Y757) signal in experimental samples?

Several technical and biological factors can lead to loss of phospho-specific signals:

When troubleshooting loss of signal:

• Verify antibody activity with a positive control sample (e.g., NGF-stimulated cells known to express NTRK1).

• Include phosphatase inhibitors (1 mM sodium orthovanadate, 10 mM sodium fluoride, 20 mM β-glycerophosphate) in all buffers from sample collection through processing.

• For tissue samples, minimize cold ischemia time (time between tissue removal and fixation) to less than 30 minutes.

• When using IHC, test multiple antigen retrieval methods and antibody dilutions to optimize signal detection .

• If signal is consistently weak, consider more sensitive detection methods like tyramide signal amplification or proximity ligation assay (PLA).

How can researchers distinguish between specific and non-specific signals when using Phospho-NTRK1 (Y757) antibodies?

Distinguishing specific from non-specific signals requires rigorous experimental controls and analytical approaches:

• Biological validation controls:

  • NTRK1 knockdown/knockout cells should show elimination of specific signal

  • Y757F mutant-expressing cells should show absence of phospho-signal

  • Unstimulated vs. NGF-stimulated comparison should show induction of signal

• Technical validation controls:

  • Phosphatase treatment should eliminate phospho-specific signals

  • Peptide competition with immunizing phosphopeptide should block specific binding

  • Secondary antibody-only controls identify non-specific secondary binding

• Signal pattern analysis:

  • Specific phospho-NTRK1 signals should correlate with known NTRK1 expression patterns

  • Subcellular localization should match expected receptor distribution (membrane, endosomes)

  • Molecular weight verification in Western blots (140 kDa for full-length NTRK1; may vary for fusion proteins)

• Cross-validation approaches:

  • Use alternative antibodies targeting different epitopes

  • Employ orthogonal techniques (mass spectrometry-based phosphoproteomics)

  • Verify with genetic approaches (e.g., CRISPR-edited cells)

For quantitative analyses, subtract background values determined from negative controls, and when possible, normalize phospho-specific signals to total NTRK1 levels to account for expression differences.

What statistical approaches are recommended for analyzing Phospho-NTRK1 (Y757) data across multiple experimental conditions?

Rigorous statistical analysis is essential for interpreting phosphorylation data across experimental conditions:

• Normalization strategies:

  • Normalize phospho-signal to total NTRK1 (preferred approach)

  • When total protein cannot be measured, normalize to housekeeping proteins

  • For IHC, use positive control tissues to normalize across batches

• Statistical tests for hypothesis testing:

  • For two-group comparisons: Student's t-test (parametric) or Mann-Whitney U test (non-parametric)

  • For multiple group comparisons: ANOVA with appropriate post-hoc tests (Tukey, Bonferroni, or Dunnett)

  • For time-course experiments: repeated measures ANOVA or mixed-effects models

• Advanced analytical approaches:

  • Regression analysis for dose-response relationships

  • Principal component analysis for multi-parameter phosphorylation studies

  • Hierarchical clustering to identify patterns across multiple phosphorylation sites

• Graphical representation:

  • For time-course data: line graphs with error bars

  • For multiple conditions: grouped bar graphs with individual data points

  • For correlation analyses: scatter plots with regression lines

• Sample size considerations:

  • Perform power analysis to determine appropriate sample sizes

  • For clinical samples, account for patient heterogeneity with larger sample sizes

  • Consider biological (different experiments) vs. technical (same experiment) replicates

When reporting phosphorylation data, always include both the absolute values and fold-change relative to control conditions, along with appropriate measures of statistical significance and effect sizes.

How can Phospho-NTRK1 (Y757) antibodies be utilized to study response to TRK inhibitors in cancer patients?

Phospho-NTRK1 (Y757) antibodies offer valuable tools for monitoring treatment response to TRK inhibitors in cancer patients:

• Pharmacodynamic biomarker applications:

  • Pre- and post-treatment biopsies to assess on-target inhibition

  • Correlation of phosphorylation inhibition with clinical response

  • Determination of optimal drug dosing and scheduling

• Resistance mechanism investigation:

  • Identification of persistent phosphorylation despite treatment (suggesting incomplete inhibition)

  • Detection of altered phosphorylation patterns indicating pathway rewiring

  • Comparison with other phosphorylation sites to identify differential regulation

• Patient stratification approaches:

  • Baseline phosphorylation levels as potential predictive biomarkers

  • Integration with other biomarkers (total NTRK1, downstream signaling activation)

  • Correlation with NTRK fusion status and fusion partner

• Liquid biopsy development:

  • Exploration of circulating tumor cells for phospho-NTRK1 detection

  • Correlation with treatment response and disease progression

  • Longitudinal monitoring during treatment

The first-generation TRK inhibitors (larotrectinib and entrectinib) have shown remarkably high response rates (>75%) in NTRK fusion-positive cancers across various tumor histologies . Phospho-specific antibodies can help determine whether incomplete inhibition of NTRK1 phosphorylation correlates with primary or acquired resistance to these therapies.

What is the significance of NTRK1 Y757 phosphorylation in neurological disorders?

While the search results focus primarily on oncology applications, NTRK1's critical role in neuronal development and function suggests important implications for neurological disorders:

• Neurodegenerative diseases:

  • Altered NTRK1 signaling, including specific phosphorylation patterns, may contribute to neuronal degeneration

  • Y757 phosphorylation status could influence neuronal survival signaling

  • Changes in phosphorylation may reflect dysregulated neurotrophin signaling

• Neurodevelopmental disorders:

  • NTRK1 signaling regulates neuronal differentiation and survival during development

  • Aberrant phosphorylation may affect neuronal circuit formation

  • Phosphorylation patterns could serve as biomarkers for developmental pathway dysfunction

• Neuropathic pain conditions:

  • NTRK1 mediates nociceptive neuronal function

  • Alterations in Y757 phosphorylation might influence pain sensitization

  • Therapeutic targeting of specific phosphorylation sites could offer novel analgesic approaches

• Methodological considerations:

  • Analysis of post-mortem tissue requires special attention to phospho-epitope preservation

  • Animal models provide opportunities for interventional studies targeting specific phosphorylation sites

  • Patient-derived neurons (from iPSCs) allow study of phosphorylation in human neuronal contexts

Understanding the specific contribution of Y757 phosphorylation to NTRK1 signaling in neurons would require careful comparative studies with other phosphorylation sites, particularly the well-characterized Y496 and Y791 residues that recruit SHC/FRS2 and PLCγ, respectively .